Flush with Eylea sales, Regeneron plots 300-job plant expansion


Regeneron ($REGN) is eyeing a big expansion at an upstate New York plant now that its macular degeneration drug has taken off. The company plans to spend $70 million on new buildings and upgrades--and add 300 jobs--at the Albany-area facility.

New York Gov. Andrew Cuomo announced the expansion, hailing it as another boost for the state's rep in the biotech world. For Regeneron, the plans reflect a more tangible accomplishment--the out-of-the gate success of its wet age-related macular degeneration treatment Eylea, which is produced at the expanding plant.

The company has had quite a year, thanks to the new drug, which was approved last November. Despite head-to-head competition from Roche's ($RHBBY) established AMD drug Lucentis--and from off-label use of the cancer drug Avastin--Eylea has racked up one sales gain after another. For the first half of the year, it brought in $318 million. By the third quarter, sales had mounted to $244 million. Now, the company is expecting Eylea revenues of at least $790 million for the year.

State and local governments are contributing to the expansion, the Albany Times-Union reports. Empire State Development will provide $6.7 million in tax credits, while Rensselaer County will tie the plant into the county's sewer system because the township of East Greenbush couldn't handle the expansion.

- see the Times-Union story

Related Articles:
Novartis balks at Eylea-vs.-Lucentis data
EU gives recommendation for Regeneron's Eylea
Regeneron keeps keeping on with Eylea
Eylea may beat Lucentis on price, but what of Avastin?
Regeneron finally captures an FDA OK with new eye drug